Aimee Donnellan is an Associate Editor at various prominent publications including Diario EL PAÍS and Reuters. She focuses on themes such as finance, trading, and healthcare, often exploring the intersections of these fields through topics like markets, business leaders, and the impact of the coronavirus. Aimee's work has been featured in notable outlets, including WAtoday, Regina Leader-Post, HELLENIC SHIPPING NEWS Worldwide, and Republic World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Aimee Donnellan's coverage predominantly revolves around finance and economy, with a significant focus on breaking news. She often covers evolving stories and relies on data to support her articles.
Given the wide array of topics covered, Aimee may be interested in pitches related to breaking financial news, emerging trends in the finance sector, or evolving economic situations. Pitches backed by solid data and insights into ongoing developments would likely resonate well with her.
Additionally, due to the diverse range of topics she covers within finance and economy, experts from various sectors such as private equity, branding, international relations or renewable energy could provide valuable perspectives for her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jonathan Guilford, Aimee Donnellan
Military escalation between Iran and Israel may at some point affect the price of oil. In this Viewsroom podcast, Breakingviews columnists debate how the conflict may prompt a fresh inflationary headache for central banks – and how Saudi Arabia might offset that risk.
Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.
Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.
Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.
By: Aimee Donnellan, Jonathan Guilford
With $31 bln of debt, deep links to the banking system and a star role in India’s energy transition, the tycoon’s empire is a crucial part of the fifth-largest economy. In this week’s Viewsroom, Breakingviews columnists discuss how US bribery charges will test those dependencies.
Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.
Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his China boss detained by Beijing and his shares underperform rivals. Yet the value which investors assign to his Middle Kingdom operations complicates a quick fix.
Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash piles of around $80 billion by 2028, according to LSEG data, thanks to the runaway success of their weight-loss drugs. The challenge will be to put that money to work and avoid overpaying.
Alcohol giants have a hazy future. Late last week, the U.S. surgeon general said beer and spirits cause cancer and should carry health warnings. The wider trend has echoes of the historic backlash against Big Tobacco, and appears to be partly factored into brewers’ depressed valuations. If the trend for less drinking continues, higher-rated spirit makers like $70 billion Diageo and $30 billion Pernod Ricard will suffer too.
Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.
(833) 317-6278 
